English
Deutsch
Français
Nederlands
Español
Reset. Heal. Grow.
Microdosing Mushrooms: What the Research Actually Shows About Psilocybin
Somewhere between the full-blown psychedelic trip and a regular Tuesday morning sits a quieter practice: microdosing. A crumb of dried mushroom — maybe a tenth of a gram — taken every few days, with no expectation of seeing the wallpaper breathe. People do it for focus. For mood. For creative work that won't unstick. For depression that hasn't budged in years. The question is whether any of it actually works, or whether we're all just very enthusiastic about placebo. The honest answer, as of 2026, is: somewhere in between, and the science is still catching up. If you're considering microdosing psilocybin — or any psychedelic — as part of your own recovery from addiction, depression, or just feeling stuck, here's what's actually known and what's still guesswork. A microdose is roughly one-tenth of a recreational dose. If a noticeable psychedelic experience kicks in around one gram of dried mushrooms, a microdose lands near 0.1 grams. Some people go even smaller. The point is that you shouldn't feel intoxicated. No visuals, no time dilation, no laughing at the ceiling. If you're tripping, you've overshot — that's a low dose, not a microdose. Psilocybin, the active compound in these mushrooms, gets converted in the body to psilocin, which binds to serotonin 2A receptors in the brain. At full doses, this rewiring produces the classic psychedelic experience — altered perception, dissolved ego, hallucinations, the works. At a microdose, the theory goes, you get subtle neurochemical effects without the cinematic ones: a small lift in mood, sharper attention, a looser kind of thinking. That's the theory. The evidence is messier. Here's where things get awkward. Several solid studies from the early 2020s — including placebo-controlled work that finally went beyond self-reported surveys — found that much of what people attribute to microdosing tracks closely with the placebo effect. In one widely cited trial, participants who thought they had taken a microdose reported nearly the same benefits as those who actually had. Expectation, it turns out, is a powerful drug all by itself. That doesn't mean microdosing is fake. It means we can't yet cleanly separate the chemistry from the belief. Both might be doing work. And given how much modern medicine accepts that mindset shapes outcome — see also: nearly every antidepressant trial ever — that's not nothing. It's just not the slam-dunk evidence that microdosing advocates sometimes claim. What the better studies do suggest is modest and worth taking seriously: Notice that last point. The studies showing the strongest mental-health outcomes almost all involve psychological support alongside the substance. Microdosing alone, with no therapy, no integration, no structure, gets you considerably less than microdosing inside a thoughtful framework. The mushroom isn't the treatment. The mushroom is one ingredient in the treatment. Microdosing has a reputation for being basically harmless — a sort of mushroom-flavored multivitamin. That's marketing, not science. Psilocybin remains a Schedule I substance in the U.S. and most other countries, which means unregulated supply, unknown potency, and zero quality control unless you're growing your own or sourcing from a meticulous friend. The actual reported side effects of microdosing include: And there's a bigger caution: people with a personal or family history of psychotic disorders — schizophrenia, bipolar I, schizoaffective disorder — should not microdose. Psychedelics can trigger or accelerate episodes in vulnerable people. This isn't theoretical. It's the single most important screening question a responsible facilitator will ask, and if nobody's asking you, that tells you something about who you're working with. No, and the difference matters. A retreat — whether it's psilocybin in Jamaica or the Netherlands, ayahuasca in Peru, or one of the legally sanctioned psilocybin programs now operating in Oregon and Colorado — uses a full dose in a held container with trained support. The intent is a single, intense experience that opens something up, followed by integration work to make sense of what surfaced. Microdosing is the opposite shape: subtle, repeated, woven into ordinary life. You go to work. You take a hike. You attend your kid's recital. The substance is supposed to fade into the background while quietly nudging your baseline. Some people use microdosing as preparation before a retreat or as part of integration afterward — both can make sense, though you should always check with the facilitators running your ceremony, because many traditions ask you to be substance-free for a meaningful window beforehand. If you're drawn to psilocybin because you're working through deep trauma, addiction, or treatment-resistant depression, the honest read is that a structured experience with proper support tends to do more than microdosing alone. Microdosing might help maintain gains or smooth out daily life. The heavy lifting often happens at higher doses with skilled people around you. A few practical things worth holding in mind before you decide anything: Microdosing is one small piece of a much larger conversation about psychedelics, master plants, and what we now call psychedelic-assisted recovery. The renaissance is real — clinical trials for psilocybin, MDMA, and ibogaine have produced some of the most striking results in psychiatry in decades. But the most dramatic outcomes come from full-dose, supported experiences, not from sprinkling tiny amounts into your morning coffee. If you're considering plant medicine because something in your life isn't working — addiction that won't lift, depression that grinds on, trauma that keeps replaying — it's worth thinking bigger than a microdose. A well-run psilocybin retreat, ayahuasca ceremony, or ibogaine program can do in a week what microdosing might do in a year, assuming microdosing is doing anything at all beyond placebo. For readers who want to explore the structured, supported route, a curated selection of psilocybin and plant-medicine retreats can be browsed on our marketplace here. Microdosing has its place. It's just probably not the whole answer — and anyone selling it as one is selling something other than the truth.
What DMT Actually Does: Inside the Science, the Trips, and the Healing Potential
Ask ten people who've smoked DMT to describe what happened and you'll get ten answers that all begin the same way: words don't really work for this. Then they'll try anyway. Spirals inside spirals. Beings that seemed to be waiting. A feeling of being yanked clean out of the body and dropped somewhere that felt — and this is the phrase that keeps coming up — more real than real. That phrase is doing a lot of heavy lifting, and it's worth taking seriously. DMT is the psychedelic compound at the heart of ayahuasca, the Amazonian brew that has pulled tens of thousands of seekers to jungle retreats over the past two decades. Understanding the molecule itself — what it does, where the research stands, and why people keep saying it changed their lives — is a useful piece of homework if you're weighing whether plant medicine is for you. N,N-Dimethyltryptamine is a short-acting psychedelic found across an absurd range of life. It's in hundreds of plants. It's in the venom of certain toads. It's been detected in every mammal researchers have bothered to test, including humans. We appear to make it ourselves, in small quantities, possibly in the lungs and the pineal gland. Nobody is entirely sure why. Smoked or vaporized, it produces a hallucinogenic experience that arrives within seconds and is largely over inside half an hour. Injected, similar story. Swallowed on its own, it does basically nothing — your gut breaks it down before it can reach the brain. That last fact is the whole reason ayahuasca exists. The traditional Amazonian brew combines a DMT-containing plant with a second plant that blocks the enzyme that would otherwise neutralize it, allowing the molecule to stay active for hours rather than minutes. So when people talk about ayahuasca, they're really talking about a way of taking DMT slowly, in a body that's been prepared by diet and ceremony, surrounded by people who know what to do when things get strange. DMT was first identified as psychoactive by Hungarian chemist Stephen Szára in the 1950s. A short, productive decade of research followed — including some investigations into whether endogenous DMT might explain schizophrenia (it doesn't). Then the 1970s arrived, drug laws tightened, and serious human research in the United States essentially stopped for twenty years. The thaw came in the early 1990s when psychiatrist Rick Strassman ran the first new DMT trials on humans in a generation at the University of New Mexico. His setup was deliberately bare: no incense, no statues, no guided meditation. He'd dose experienced volunteers in a hospital room and ask them to report back. The point was to see what the molecule did, stripped of expectation. What they reported was strange enough that Strassman went on to write a book about it. Volunteers described being pulled out of their bodies. Encountering entities that seemed intelligent and aware of being observed. Visiting places that didn't behave like physical space. One woman came back from her session convinced — calmly, matter-of-factly — that consciousness continues after death. If everyone knew what was waiting, everyone would commit suicide, she told him. He suggested she keep that to herself. Here's the thing that makes DMT genuinely different from other psychedelics. Mushrooms and LSD tend to modify your relationship with the world you're already in — colors smear, walls breathe, your sense of self softens. A DMT experience, by contrast, tends to feel like leaving entirely. Users describe a sensation of being launched. The geometry of ordinary space falls away and is replaced by something that operates on different rules — recursive fractals, impossible architectures, what one person I spoke with called "the back end of the simulation." Time becomes meaningless. Language follows. People often report telepathic exchanges with whatever they encounter in there, and a peculiar sense that the encounter is the point. A few recurring figures appear often enough across reports that there are entire online forums devoted to them — the jester, the mantis, the machine elves popularized by Terence McKenna. Whether these are projections of the human mind under extreme neurochemical pressure or something stranger is a question the science cannot currently answer. Probably won't anytime soon. The connection between DMT and death — or near-death — has been around long before the chemistry was understood. In Quechua, ayahuasca roughly translates to vine of the dead or vine of the souls. The traditional belief is that drinking the brew opens a doorway to the realm of disembodied spirits. The Shipibo, Shuar, and other Amazonian peoples have organized substantial portions of their cosmology and medicine around this idea for centuries. Modern interest in this overlap took off when researchers noticed that the standard near-death experience — the tunnel of light, the loving presence, the life review, the reluctance to come back — sounds an awful lot like a strong DMT trip. There's a hypothesis, still unproven, that the dying brain releases a flood of endogenous DMT as a kind of farewell. Some unpublished animal data suggests DMT levels do rise in the brain at death. It's not nothing, but it's not yet a settled case either. What we can say honestly: Whether any of that means DMT is a cosmic doorway or just an unusually interesting neurochemical, I'll let you decide. This is where things get practical for anyone reading because they're thinking about a retreat. The therapeutic conversation around DMT — and, by extension, around ayahuasca — has shifted dramatically in the last decade. Researchers have looked at ayahuasca for treatment-resistant depression, PTSD, grief, and addiction recovery. The early results are genuinely promising, particularly for people who've tried conventional treatments and come up empty. One reason DMT is hard to study clinically is that the experience is so short. Strassman and his colleague Andrew Gallimore published a paper proposing a way to deliver DMT via continuous infusion — essentially a steady IV drip that could hold someone in the state for hours rather than minutes. The reasoning is medical, not recreational: a sustained experience allows for actual therapeutic work, which is impossible to do during a fifteen-minute blast. This is also, in a sense, what ayahuasca already does. The brew stretches a DMT experience across four to six hours, long enough for emotional material to surface, be witnessed, and begin to integrate. Talk to people who've done plant medicine for trauma or addiction and you'll hear versions of the same arc: the substance shows them something they'd been avoiding, and the actual healing happens in the weeks and months afterward, in therapy, in journaling, in the slow business of changing how they live. One of Strassman's volunteers described looking back on her childhood with a clarity she'd never had sober. Another came back with strong feelings about needing to spend more time with family. A man I corresponded with — call him Sam — told me he'd been planning suicide before he tried DMT. He described the experience as the universe holding him in something that felt like oceanic love. Afterward, the cynicism that had been suffocating him simply lifted. He started living again. I include that not as a sales pitch. Plenty of people have difficult, frightening, or genuinely traumatic experiences with DMT and ayahuasca, especially when set and setting are wrong. But the testimony of people who feel they were pulled back from something terminal is consistent enough across decades and continents that it deserves to be taken seriously. Something is happening in there. A few practical points for the reader who's been Googling at midnight, weighing whether to actually do this: DMT — and ayahuasca specifically — is not for everyone, and the people running ethical retreats will tell you so. It's a powerful tool that happens to suit certain people at certain points in their lives, and it sits alongside therapy, breathwork, meditation, and a hundred other options that may serve you better depending on where you are. If after reading this you find yourself genuinely curious rather than just intellectually interested, that's worth listening to. For readers who want to take this further, a range of ayahuasca and plant medicine retreats can be browsed on our marketplace here. Take your time with the decision — the medicine, whatever you believe about it, has been around for centuries and isn't going anywhere.
Ibogaine Retreats Explained: What a Psychospiritual Journey Actually Involves
The first time someone tells you about ibogaine, they usually say something like, “It showed me my entire life in one night.” That's the line. It gets repeated in recovery rooms, on forums, in late-night phone calls between people who've been chewing on the idea of a retreat for months. And it's not exactly wrong — but it's also not the whole story. Ibogaine is one of the heaviest plant medicines on the planet. Heavier than ayahuasca in some ways. Longer than psilocybin. More physically demanding than almost anything else in the psychedelic landscape. It's also the substance with the most credible track record for interrupting opioid addiction, which is why people in genuine crisis end up googling it at three in the morning. If that's where you are, or if you're somewhere further back in the research process, here's an honest look at what ibogaine retreats actually involve. Ibogaine is an alkaloid extracted from the root bark of the iboga shrub, which grows in the rainforests of central west Africa — Gabon, Cameroon, parts of Congo. In its traditional context, iboga is used by the Bwiti, an initiatory spiritual tradition where the plant is taken in large quantities during multi-day rites of passage. It's a master plant in the truest sense: revered, feared, treated with enormous care. In the modern psychedelic and addiction-recovery world, ibogaine usually shows up in one of two forms. There's purified ibogaine HCl, which is what most medical-model clinics use because the dose is precise. And there's total alkaloid extract or whole root bark, which keeps the full spectrum of compounds intact and is more common in psychospiritual or Bwiti-influenced retreats. Different teachers prefer different forms for different reasons, and neither is automatically better. The experience itself lasts a long time. Plan on twelve to twenty-four hours of active effects, followed by another day or two of what people call the “gray day” — exhausted, raw, processing. Most retreats keep you on-site for at least a week. The biggest single reason is addiction. Specifically opioids — heroin, fentanyl, oxycodone, methadone — because ibogaine has a documented ability to dramatically reduce or eliminate physical withdrawal in a single session. That's not marketing. It's been observed clinically since the 1960s, and there's enough peer-reviewed research now that several countries treat ibogaine as a legitimate (if still experimental) addiction intervention. People walk into a clinic strung out and walk out, days later, without the gnawing physical craving. That alone is reason enough that ibogaine retreats exist. But opioid recovery isn't the only doorway. Plenty of people arrive looking for something else entirely: Ibogaine has a reputation, deserved, for being unusually direct about showing you your own life. Where ayahuasca tends to move in waves of imagery and emotion, ibogaine often feels more like watching a documentary about yourself. The memories that surface are specific. The lessons feel almost lectured. People describe meeting parts of themselves they'd written off, or seeing a relationship in completely new terms, or understanding — finally — why they keep doing the thing they keep doing. You'll usually start in the evening, after a medical screening earlier in the day. The room is dark or low-lit. You're lying down — and you'll stay lying down, because ibogaine produces ataxia, which means your coordination is gone. Standing up is a bad idea for many hours. The first phase, often called the visionary phase, comes on within an hour or two. Eyes closed, you start seeing — and the word “seeing” is doing a lot of work here. Some people describe it as a flood of autobiographical memory played at high speed. Others get more symbolic, archetypal material. Many hear a buzzing or whirring sound, almost mechanical. There's frequently a sense of being shown something by an intelligence that isn't you. Whether you call that the plant, the unconscious, or something else is up to you. The second phase is more reflective. The flood slows. You're still inside the experience but able to think about it, examine specific scenes, ask questions and get answers. This can go on for hours. Time becomes essentially meaningless. The third phase is the long tail. Physical exhaustion, sensitivity to light and sound, sometimes nausea, and a strange kind of mental clarity that sits underneath the tiredness. Sleep often doesn't come for another day. When it finally does, it's usually deep. Ibogaine is the psychedelic with the most serious safety profile concerns, and any retreat worth its fee will tell you this upfront. The risk isn't really psychological — it's cardiac. Ibogaine prolongs the QT interval, which in plain language means it can disrupt the electrical rhythm of the heart. In a healthy screened person, in a properly run setting, this risk is manageable. In an unscreened person with an undiagnosed condition, it can be fatal. Non-negotiables when evaluating a retreat: If a retreat is cagey about any of these, walk away. There's no version of ibogaine where the spiritual depth justifies skipping the medical infrastructure. The retreats with the best long-term outcomes are also, without exception, the ones with the strictest screening. The ibogaine world is smaller than the ayahuasca world, but it's grown fast in the last few years, and not every operation is equal. A handful of things to look at: Lineage and training. Is the lead facilitator trained in a recognized tradition or by a recognized medical body? Bwiti-trained practitioners, ibogaine providers who came up through GITA-aligned programs, clinicians with addiction-medicine backgrounds — these are signals. Vague spiritual credentials are not. Integration support. The ceremony is maybe a third of the work. What happens in the weeks and months afterward decides whether the insight lands or evaporates. Reputable retreats offer post-retreat integration calls, group sessions, or referrals to integration coaches. If the relationship ends when you leave the property, that's a red flag. Honesty about what ibogaine can't do. If a retreat promises a cure, run. Ibogaine interrupts patterns. It opens a window. What you do with that window is on you — and on whatever support structure you build around it. A facilitator who says this plainly is more trustworthy than one who promises transformation. Reasonable group size. Ibogaine isn't a group ceremony in the ayahuasca sense. Each person needs close attention. Be skeptical of large cohorts. The preparation window matters more than people realize. A few practical things: Get your medications sorted with your prescribing doctor well in advance. SSRIs and SNRIs typically need to be tapered weeks before, not days. Methadone has its own long timeline. Buprenorphine has its own. Stimulants, including ADHD medications, need to be cleared. Do not improvise this part. Eat clean for at least a couple of weeks before — less sugar, less alcohol, more whole foods. Your body is about to do something difficult; show up rested. Sleep matters more than any superfood. Spend some honest time with the question of what you actually want from the experience. Not the spiritual version of the answer — the real version. “I want to stop using” is real. “I want to know why I've sabotaged every relationship I've had” is real. “I want to feel something other than numb” is real. Write it down. Bring it with you. And tell someone you trust what you're doing. Not for permission — you're an adult — but because integration is easier when you have at least one person who knows where you went and is curious to hear what came back with you. The week after is strange. You'll feel physically tender for a few days. Emotionally, many people report a kind of quiet — the constant background noise of craving or self-criticism turned way down. This is sometimes called the “afterglow,” and it can last weeks. It's a window. Use it. Build something during this period. Therapy appointments scheduled. New routines actually started. Honest conversations actually had. The ibogaine showed you the map; the walking is yours to do. People who treat the retreat as the end of the work tend to drift back toward where they started within months. People who treat it as the beginning tend to be having different conversations a year later. For readers who want to take this further, a range of vetted ibogaine and plant-medicine retreats can be browsed on our marketplace here. Take your time with the decision — the right retreat is worth waiting a few months for, and the wrong one isn't worth any price.
Psychedelics for PTSD: Real Stories of Healing With MDMA and Ayahuasca
The first time Nathan closed his eyes during the trial, he described it like a kid pulling back heavy curtains in a room he’d been afraid of for years. He wasn’t scared anymore. He was curious. That single shift — from dread to curiosity — is something I hear over and over from people who turn to psychedelics for PTSD, and it’s usually where the real work begins. Stories like Nathan’s are part of why interest in psychedelic-assisted therapy has gone from fringe to front-page. MDMA, psilocybin, ayahuasca, ibogaine — none of them are silver bullets, and anyone honest in this field will tell you that. But a growing body of research, plus thousands of personal accounts, suggests these compounds can do something traditional treatment often can’t: help a traumatized nervous system feel safe enough to actually process what happened. Below are several real accounts — drawn from veterans, survivors, and clinical-trial participants — of what it actually feels like to face PTSD with the help of plant medicine and psychedelics. I’ve sat with people during and after experiences like these. The patterns repeat. The details never do. PTSD is stubborn. SSRIs help some people a little. Talk therapy helps more people, but slowly, and not everyone. For combat veterans, sexual assault survivors, and people carrying the weight of childhood trauma, the standard menu can feel exhausted before they’ve really started. That’s where psychedelics — and the broader category of master plants — keep entering the conversation. The research is genuinely promising. MDMA-assisted therapy is in late-stage clinical trials with MAPS, and early data has been strong enough that the FDA granted it Breakthrough Therapy designation. Psilocybin is being studied for treatment-resistant depression, end-of-life anxiety, and trauma. Ayahuasca, traditionally brewed in the Amazon for centuries, has drawn veterans’ groups who travel to legal jurisdictions because they’ve simply run out of options at home. None of this means you should go book a flight tomorrow. It does mean the desperation a lot of trauma survivors feel — that nothing is working — is finally being met with serious science and serious facilitators. The question is whether a retreat or trial is the right fit for you, right now. One former special-operations sergeant I’ll call C., 37, spent sixteen years in the military. By the time she got her PTSD diagnosis, she was preparing for another deployment and quietly aware she was no longer fit to lead her team. Antidepressants didn’t move the needle. Rehab helped with the drinking. The trauma itself — childhood and what came later in uniform — sat untouched. She heard about ayahuasca on a podcast, fell down the research rabbit hole, and eventually ended up at a retreat in Mexico that combined psilocybin and MDMA in a ceremonial setting. Lying among other participants, eye mask on, music playing, her body started shaking — not from fear, she said, but from something almost warm. Her chest felt like it was being held open. What she keeps coming back to isn’t the visions. It’s the absence of shame. For a few hours she existed without the constant low hum of guilt that had followed her for decades. That’s not a cure. But for someone who’d forgotten what neutral even felt like, it was the first crack of daylight. Another veteran, a former paralegal and combat driver, joined a retreat in 2021 after a year of talk therapy and several months of one-on-one prep with a coach. The retreat itself required strict dieta beforehand — no caffeine, no sugar, no alcohol, no salt, no stimulants. Participants journaled. They talked in circles. They got clear on what they were actually there for. She described the ceremony as drifting in and out of consciousness. When she came to, she felt the brew moving inside her — up to her throat, down through her stomach, swirling in her pelvis. She kept repeating, quietly, thank you for healing me, thank you for showing me, for what she remembers as about four hours. She’s firm about one thing: psychedelics are not a one-and-done fix. “Healing should be multidisciplinary,” she told me. “It’s a buffet. You don’t eat one thing and hope it lasts forever.” That line should be tattooed on the inside of every retreat brochure. Rudy, an 18-year special forces operator, had never touched an illicit drug before his first ayahuasca ceremony. His marriage had collapsed. He’d had an emotional breakdown. The VA had offered him what he called a cornucopia of pharmaceuticals, and he’d watched what those same prescriptions had done to friends. He said no. The symptoms were textbook combat PTSD — waking up convinced he was still deployed, snapping at things that didn’t matter, suffocating in crowds. One night he came back to consciousness standing naked at his own front door with a pistol, certain his teammates were about to be overrun. It was his wife’s voice that pulled him back. He flew out for ayahuasca through a veterans-focused organization. Months later, he didn’t describe himself as fixed. He described himself as having a new template for processing experience. The combat memories are still there. They just don’t run the show anymore. He also, in his words, left several buckets of vomit at the retreat — and joked that the shaman called him a strong purger. That kind of humor, in my experience, is a good sign someone is genuinely on the other side of something. Not every story takes place in a jungle. Lori, 42, was one of the early participants in MAPS’s FDA-cleared MDMA trials. Her trauma history is the kind that breaks sentences in half: her brother’s overdose, a rape by someone she knew, and walking in on the aftermath of a murder-suicide committed by her own mother. She received MDMA in three guided sessions, sandwiched between talk-therapy preparation and structured integration afterward. What she stresses — and what facilitators stress — is that the integration phase is where a lot of the actual healing settles in. The drug isn’t the therapy. The drug opens a window. What you do with what you saw, over the following weeks and months, is the therapy. This is where I see retreats and trials fail people most often. The ceremony is dramatic. The aftermath is quiet. Without integration — journaling, therapy, somatic work, community, time — it’s easy to slide back into old grooves and wonder why the magic didn’t stick. If you’re reading this because you’re weighing a booking, here are the questions I’d want you sitting with before you wire any deposits: I’ll be honest — the psychedelic space attracts both genuine healers and a fair number of opportunists with good lighting. Vet your facilitators the way you’d vet a surgeon. Read participant accounts that aren’t on the retreat’s own website. Talk to people who attended a year ago, not last week — because the year-later picture is what actually matters. A lot of people, understandably, can’t afford a structured retreat or wait years for a trial. Microdosing and underground experiences are everywhere. Researchers in this field — including the ones running the trials — consistently warn that self-medicating powerful compounds without screening, set, setting, or support can surface material people aren’t prepared to hold. That’s not a moral judgment. It’s a practical one. Trauma stored in the body has its own logic. When it comes up uninvited, in a context with no facilitator and no integration, it can entrench rather than release. If you’re going to do this work, give yourself the conditions to do it well. What strikes me about the people in these stories isn’t the drama of the ceremonies. It’s the ordinariness of what they wanted afterward — to sleep through the night, to be present with their kids, to stop bracing against everything. Psychedelics didn’t hand that to them. The medicine cracked something open, and they did the unglamorous work of rebuilding from there. If any of this resonates and you want to take a careful next step, a curated selection of ayahuasca and psychedelic retreats — including options that work specifically with veterans and trauma — can be browsed on our marketplace here. Take your time. The right retreat will still be there next month.
Bufo Alvarius: What a 5-MeO-DMT Ceremony Actually Feels Like
Someone asked me once, very casually, over tea: “You've sat with ayahuasca, you've done kambo — but have you ever smoked the toad?” The way they said it made the question land differently. Like they were quietly checking whether I knew what I was getting into. Bufo, they kept telling me, is something else entirely. Why, I wondered, would anyone willingly sign up to feel like they're dying? And yet here I am, writing about the night I did exactly that. This is a long piece about Bufo alvarius — what the medicine is, where it comes from, what the ceremony looked like from the inside, and what stuck around afterward. If you're researching whether to sit with 5-MeO-DMT yourself, I'd rather you read an honest account than a glossy one. Bufo refers to the dried venom of the Sonoran Desert toad — Bufo alvarius, also called Incilius alvarius by the people who care about taxonomy. The toad lives in a narrow band of desert across northern Mexico and the American Southwest. Its parotid glands secrete a milky substance loaded with tryptamines, the most notable being 5-MeO-DMT, which is widely considered the most potent naturally occurring psychedelic on the planet. The secretions are harvested without killing the animal, then dried into small crystalline flakes. Those flakes get loaded into a glass pipe, gently heated, and inhaled in a single slow breath. The effects arrive almost immediately. Total duration is usually fifteen to twenty minutes by the clock. Inside the experience, time is meaningless. People come back saying it felt like forever, or like no time at all, or both. This is worth pausing on: 5-MeO-DMT is not the same as the N,N-DMT found in ayahuasca. The visual character is different. The emotional terrain is different. Ayahuasca tends to give you a narrative — scenes, memories, conversations with something that feels like an intelligence. Bufo tends to dissolve the narrator entirely. There's no story. There's just whatever is left when the story-maker stops. For a long time my answer was a polite no. The reports I heard sounded too intense, too close to actual ego death, too much like the dying I wasn't ready for. I had two kids at home. I had work I cared about. I wasn't running away from anything obvious, and I couldn't find a clean reason to invite something that felt this big. Then a stranger messaged me about a ceremony happening the following week, on the one open evening between Christmas and New Year — the only unscheduled day in a packed month. I'm not a sucker for coincidence, but my body said yes before my mind could argue. So I went. If you're considering Bufo, I'd offer this: pay attention to how the invitation arrives. Are you chasing it because you've seen testimonials on Instagram and you want what those people seemed to get? Or has it shown up in your life with a strange quiet insistence that you can't quite explain away? Those are different motivations, and they tend to produce different ceremonies. The ceremony was on the top floor of an old building near a canal in Amsterdam. Steep stairs, creaking floors, about ten of us sitting on cushions in a circle. Sage smoke. A small altar with feathers and a few stones. None of it was theatrical. It looked, honestly, like somebody's living room arranged with care. The facilitator — I'll call him Raul — opened by saying he wasn't a shaman. “We're each our own shaman,” he said. “I'm just here to sit with you while it happens.” Every actual shaman I've met says some version of this. The ones claiming the title outright are almost always the ones to avoid. His partner translated from Spanish into English. They explained what the medicine does and doesn't do, what to expect physically, what might come up emotionally, and what they would do if someone struggled. They told us bluntly: the body can feel heavy. The body can feel orgasmic. The ego dissolves. You may not remember who you are. They asked each of us to set an intention. People went one at a time. Raul would load the pipe, heat it, and guide the person to breathe out, then inhale slowly and hold. Within seconds, most of them either lay back voluntarily or were gently lowered to the floor. Then came the next fifteen or twenty minutes — completely different for everyone. Some people went silent and motionless. One person sobbed. One laughed for nearly the entire time. One thrashed for two minutes and then went still and beatific. Raul's response shifted with each — sometimes singing, sometimes waving a feather, sometimes just sitting nearby looking unbothered. There was no formula. He read each person and responded. What surprised me, watching, was how unlike kambo this looked. Kambo is loud — the racing heart, the purging, the heat. Bufo was quieter on the outside. The whole drama was happening internally. That calmed me down a little before my turn. When they called me up, my main fear wasn't death itself. It was leaving my kids without a mother. But everyone in the circle had returned from their own dying, so I figured I could too. I'd later come to think of that moment — the willingness to let go even briefly — as the actual work. The smoke is just the vehicle. The pipe touched my lips. It tasted like singed hair and something organic I'd rather not name. I relaxed my throat and kept drawing it in until Raul said stop. Hold. The drop was immediate. I felt myself fall backward into the floor — into the earth beneath the floor — while a warm, overwhelming light filled my visual field. Behind my eyelids, fractals rushed toward my forehead at speeds I had no reference for. Most were drenched in color. Some were stark black and white. Waves of sensation moved through me that I genuinely have no language for. So this, I thought from somewhere, is what dying feels like. What I learned in those minutes — and this is the only practical thing I can really offer you — is that resistance and surrender produce wildly different experiences inside the same medicine. When my thinking mind tried to assert itself (should I make sounds? should I move?) the colors dimmed and a harsher, more judgmental texture crept in. When I let go and dropped attention back into the fractals, the beauty returned. The choice point was right there, over and over. That's the practice. I sat up, eventually. Raul was in front of me. We held eye contact for what felt like a long, wordless conversation. My mind was already running its usual program — did I do that right? what now? — but underneath it was a quieter knowing that didn't need anything from me. We bowed. He leaned in and said one word in my ear that happened to be the exact word I'd been working with all year. I won't share it. It would mean nothing to you and everything to me. For about a week, I felt soft and porous in the best way. More love in my chest. Easier tears at small things — strangers laughing on a tram, my kid drawing something terrible and showing me proudly. Also, oddly, the world felt slightly flat. The colors of ordinary life were duller, as if I now knew about a dimension that wasn't currently accessible. This is normal. Integration after 5-MeO-DMT can include a kind of homesickness for the state the medicine showed you. Some people report a low or grey period in the second or third week. Some get the opposite — sustained joy, clarity, a quieter inner critic. Most get some of both. If you're thinking about sitting with Bufo, plan your calendar accordingly. Don't book a ceremony the night before a job interview or a wedding you have to host. I can't answer that for anyone else. What I can say is that Bufo is not a beginner medicine, and it's not a substitute for therapy, recovery work, or the long slow building of a life you actually want to be in. It's a brief, extraordinary look at something — call it consciousness, call it presence, call it whatever you want — and what you do with that look is the rest of the work. If you're drawn to it because ayahuasca felt too long, kambo too physical, or psilocybin too narrative — fair enough. If you're drawn because you want a shortcut past your trauma, please reconsider. There are no shortcuts. The medicine can crack open a door; walking through it is still on you. For readers who feel quietly called to take this further, a curated selection of 5-MeO-DMT and broader plant-medicine retreats can be browsed on our marketplace here. Take your time choosing. The right ceremony will still be there when you're ready.
Craving More Stories?
Join our ShopAyahuascaRetreats newsletter for the latest updates on thrilling
destinations and inspirational tales, delivered straight to your inbox!
We value your privacy. Your email address will never be shared or published.
Why Silicon Valley Money Is Pouring Into Psychedelics Startups
Something strange is happening at the intersection of psychedelics and Silicon Valley. The same investors who funded scooter apps and food-delivery platforms are now writing checks to companies developing the next generation of psychedelic-assisted therapies. If you'd told me a decade ago that the world's most famous startup accelerator would be backing magic-mushroom research, I'd have laughed into my mug of mapacho tea. And yet here we are. Analysts have floated numbers north of $100 billion for the future psychedelics market, and the money is moving accordingly. For anyone researching ayahuasca, ibogaine, psilocybin, or other master plants — whether for addiction recovery, depression, or just the kind of stuck life pattern you can't seem to shake — this matters. The infrastructure behind plant medicine is changing fast, and what gets built (or doesn't) over the next five years will shape the retreats, clinics, and protocols you'll eventually choose between. The short answer: clinical results, decriminalization momentum, and an addiction-and-depression crisis that mainstream pharma hasn't dented. SSRIs have plateaued. Opioid overdoses keep climbing. Veterans are dying by suicide at rates that should embarrass everyone. Into that vacuum walks a body of research — much of it from Johns Hopkins, NYU, Imperial College London, and MAPS — suggesting that compounds like psilocybin, MDMA, and ibogaine produce meaningful, sometimes durable improvement after just one or two sessions. Investors smell a fundamental shift. Not incremental. Generational. When something works better than the current standard of care and the regulatory door is creaking open, capital floods in. That's the boring, predictable part. The interesting part is what those investors choose to fund. The famed Y Combinator accelerator — the one that backed Airbnb, DoorDash, and Dropbox before anyone knew their names — has quietly admitted several psychedelics companies to its program. A spokesperson was careful to say YC doesn't pick industries, it picks teams. Fair enough. But the fact that four psychedelics startups cleared a roughly 1.5% acceptance bar tells you something about where smart money thinks the puck is heading. A handful of YC-backed companies give a useful snapshot of the space. None of them run retreats. All of them are building the scaffolding around the medicines themselves. What's striking is the range. One company is building clinical software. Another is doing computational drug design. A third is running traditional pharma R&D with a psychedelic twist. None of them are running ceremonies in the jungle. That distinction matters more than it might seem. Here's where things get philosophically interesting, and where I'll be honest about my own bias. I've sat in ayahuasca ceremonies. I've watched people work through grief, trauma, and addictions that years of talk therapy hadn't budged. The thing that made those experiences powerful wasn't the molecule alone — it was the container. The shaman who knew when to sing and when to be silent. The dieta beforehand. The integration circle the next morning. The jungle itself. Venture-backed psychedelics is a different beast. It's optimized for FDA approval, insurance reimbursement, and scalable clinical delivery. That has real upside: standardized dosing, medical oversight, fewer cowboys offering "ceremonies" in suburban living rooms. It also has real costs. The ceremonial context — the lineage, the songs, the relationship with the plant as a being and not a compound — doesn't fit neatly on a Series A pitch deck. For readers weighing whether to fly to Peru, Costa Rica, or Mexico for a traditional retreat versus waiting a few years for a clinical option closer to home, the trade-offs are worth thinking about honestly: None of these paths is automatically right. What matters is matching the path to what you're actually working with. Someone with treatment-resistant depression and no trauma history might do beautifully in a clinical setting. Someone unwinding decades of complex PTSD or wrestling with addiction often needs the longer arc and ceremonial holding that retreats provide. A hundred billion dollars sounds like it could solve a lot of problems. It won't solve the ones that matter most. It won't teach a facilitator how to sit with someone in their darkest hour without flinching. It won't replicate the apprenticeship of a curandero who learned from their grandmother who learned from hers. It won't undo the extractive history of foreign companies patenting compounds that indigenous people have used for generations. And — this is the quiet part nobody at a pitch meeting wants to say — it won't change the fact that psychedelic healing is hard, often uncomfortable, and absolutely not a shortcut. I've seen people come back from a retreat changed in ways that lasted years. I've also seen people come back convinced they were healed, then quietly relapse six months later because they skipped the integration work. The medicine is not the cure. The medicine cracks something open, and then the actual work begins. No amount of venture funding changes that math. Both. Probably more good than bad, if I'm being fair. Legalization and clinical access mean people who would never travel to the Amazon — veterans, people with chronic illness, people without passports or PTO — will eventually get access to compounds that could genuinely help them. That's worth a lot. The risk is monoculture. If clinical models dominate the conversation, the ceremonial traditions get framed as quaint, unscientific, or unsafe — even when they've been refined over centuries and produce outcomes the studies are only beginning to measure. The best future is one where both exist, where someone can choose a six-day ayahuasca retreat with a vetted lineage or a structured psilocybin protocol at a clinic forty minutes from home, depending on what they need. For readers who want to take this further, a range of curated plant-medicine and psychedelic retreats can be browsed on our marketplace here — useful if you're weighing the traditional side of the equation against the clinical wave that's still a few years out. Whichever path you find yourself drawn to, do the homework. Talk to people who've sat with the specific medicine you're considering. Ask facilitators uncomfortable questions about training, safety protocols, and what happens if something goes wrong. The money rushing in will eventually make this whole landscape safer and more accessible. Until it does, your discernment is the most valuable thing in the room.
The Psychedelic Renaissance: Why Science Is Revisiting Plant Medicines for Addiction and Depression
Something strange has happened over the past decade. Substances that were treated as cultural radioactive waste for half a century — LSD, psilocybin, mescaline, MDMA, ayahuasca — are now being studied at Johns Hopkins, Imperial College London, NYU, and a growing list of universities that wouldn't have touched this work in 1995. Psychedelics and the broader family of master plants are no longer fringe. They're showing up in peer-reviewed journals, in regulatory filings, and in conversations between therapists and clients who have run out of other options. If you're researching a retreat — quietly, maybe a little nervously — you've probably noticed the shift too. The tone has changed. The people writing about plant medicine for addiction recovery aren't all wearing tie-dye. Some of them are clinicians. Some are veterans. Some are recovering executives who tried everything else first. So what actually happened? Why did the science come back, and what does the current evidence really say? Most people forget — or were never taught — that there was a first wave. Between roughly 1950 and the late 1960s, more than a thousand scientific papers were published on psychedelics. Humphry Osmond, the British-Canadian psychiatrist who actually coined the word psychedelic in 1957, was treating alcoholics with LSD and getting results that would make a modern addiction researcher sit up straight. Mescaline, freshly synthesized from the peyote cactus, was being studied alongside Albert Hofmann's LSD, which Sandoz had been distributing to researchers since 1938. Then the door slammed shut. A combination of factors — the CIA's grotesque MK-Ultra mind-control program, Timothy Leary turning Harvard into a self-promotion machine, alarmist government films, and a recreational scene that genuinely did produce casualties — collapsed the entire research field. By 1970, the Controlled Substances Act in the U.S. had placed these molecules in Schedule I, the most restrictive category. Studying them legally became almost impossible. Careers built on that work evaporated. Here's the part that gets glossed over: the science didn't die because the science was bad. It died because the political climate made the science unfundable and the researchers unemployable. Promising data on alcoholism, end-of-life anxiety, and depression simply sat on shelves for decades, waiting. The thaw started slowly. In 2009, Britain's chief drug adviser David Nutt publicly argued that alcohol and tobacco were measurably more harmful than LSD, MDMA, and psilocybin. He was fired. But his data — and the controversy — cracked something open. Other established researchers began publishing again. MAPS (the Multidisciplinary Association for Psychedelic Studies) and the Beckley Foundation kept funding work that universities were too nervous to underwrite directly. The findings that emerged over the next decade and a half are the reason you're reading this article today: None of this means psychedelics are a miracle. It means the evidence base has grown thick enough that ignoring it is no longer intellectually defensible. If there's one thread that keeps surfacing in this work, it's addiction. The early Saskatchewan LSD trials in the 1950s were aimed at alcoholism. Modern psilocybin work has revisited that exact question and found echoes of the same results. Ayahuasca retreats in Peru and Costa Rica are quietly full of people working on alcohol, cocaine, and opioid dependence. Ibogaine, derived from the iboga root in West Africa, has built its underground reputation almost entirely on opioid interruption. Why? The honest answer is that nobody fully knows. The leading theories involve a combination of neuroplasticity — these substances appear to make the brain temporarily more flexible — and the psychological experience itself, which often delivers something that feels like a confrontation with whatever the person has been avoiding. Patients describe seeing the shape of their own behavior from outside it, sometimes for the first time. That's not a mechanism a pharmaceutical company can patent, which may be part of why the research took so long to come back. The takeaway for someone considering plant medicine for addiction: this is a serious avenue worth taking seriously, but it isn't a one-shot cure. The people who get lasting benefit tend to do real preparation, real integration, and real life-restructuring afterward. The ceremony is the doorway, not the destination. Here's where the current renaissance differs from the 1960s in a way that actually matters. The first generation of researchers tried hard to isolate the molecule from its context. That was the dominant scientific instinct of the era — strip away the ritual, the music, the setting, the shaman, and measure the chemical. The randomized controlled trial, which became the gold standard of pharmacology, is built on exactly that logic. It turns out that with psychedelics, you can't really do that. Set and setting — the mindset you bring and the environment you're in — shape the experience more than the dose does, past a certain point. The Indigenous traditions that had been working with ayahuasca, peyote, and psilocybin mushrooms for centuries already knew this. They built elaborate frameworks around the medicine: dietary preparation, songs, intentions, community, aftercare. Modern researchers are, somewhat sheepishly, beginning to admit that those frameworks aren't decoration. They're part of what makes the medicine work. This is why the better retreats today combine clinical seriousness with traditional practice. The facilitators have read the papers and spent years apprenticing with elders. Neither half alone is enough. If you're sitting at your laptop wondering whether to actually do this — book a flight, take time off work, drink something that will reorganize your inner life for a few hours — the science gives you reasons to take the option seriously. It doesn't give you reasons to be reckless. A few things worth thinking through honestly: The psychedelic renaissance is real, the evidence is meaningful, and the door that closed in 1970 is genuinely open again — but as a participant, not just an observer, you're walking into something that asks for respect. For readers who want to explore this further, a thoughtfully curated range of ayahuasca and plant-medicine retreats can be browsed on our marketplace here. Take your time. The medicine isn't going anywhere, and neither is the question you're trying to answer.
Microdosing Psychedelics for Focus and Creativity: What's Really Going On
Somewhere between the third coffee and the Sunday-night dread, a quiet question has started showing up in group chats and on private Substacks: is microdosing actually doing something, or are these people just unusually disciplined about their sleep? The trend has crept out of the Bay Area and into ordinary lives — teachers, lawyers, recovering workaholics, people in their fifties who haven't touched anything stronger than wine since college. Psychedelics, in tiny sub-perceptual doses, have become an open secret. This isn't a sales pitch for it. It's a walk through what the practice actually is, what the (still limited) research says, who tends to benefit, who probably shouldn't bother, and how the whole conversation connects to the broader world of plant medicine and psychedelic healing. If you're researching this because you're stuck — in a job, a mood, an addiction, a relationship pattern — you deserve specifics, not vibes. A microdose is a fraction of a recreational dose — usually somewhere between a tenth and a twentieth. The point is to feel almost nothing. No visuals, no ego dissolution, no giggling at the carpet. The two most common substances are psilocybin (dried mushrooms, typically around 0.1–0.3 grams) and LSD (around 5–15 micrograms). DMT and mescaline get mentioned occasionally but are less practical for daily use. People follow protocols. The best known is the Fadiman protocol — one day on, two days off, repeated for a month or two, then a break. Others go every other day, or Monday/Wednesday/Friday. The schedule matters because tolerance builds quickly with classic psychedelics, and the days off are when most users report the lingering benefits. One thing worth saying clearly: these substances remain illegal in most countries, including most of the United States. A handful of jurisdictions — Oregon, Colorado, certain cities — have begun decriminalizing or regulating psilocybin in specific contexts. The legal picture is shifting, but it hasn't shifted as much as the headlines suggest. The reasons I hear most often, in roughly descending order: Founders and engineers tend to get the press, but the population of people microdosing now is far broader than that. Parents in their forties working through burnout. Veterans cautiously experimenting with their PTSD. Recovering drinkers using it (sometimes alongside therapy) to soften the edge of early sobriety. Here's the honest part: a lot of what's reported is also placebo, and the placebo isn't necessarily a bad thing — it's just not magic. A 2021 study from Imperial College London compared people microdosing psilocybin with people who only thought they were. Both groups felt better. The differences were small. That doesn't mean microdosing does nothing; it means we don't yet have the clean data to say what it does beyond expectation effects. If you've found your way to this article, you're probably also reading about ayahuasca, ibogaine, psilocybin retreats, and the broader category of master plants. It's worth understanding how microdosing relates to those — because they're often discussed together but they do quite different things. A full ayahuasca ceremony, or a high-dose psilocybin session in a clinical or retreat setting, is a discrete event. You sit with it for hours. You may meet something inside yourself that you've been avoiding for twenty years. The work is intense, often uncomfortable, and the integration afterward can take months. People who go deep with master plants typically describe one or two ceremonies as more impactful than years of therapy. Microdosing is the opposite shape. It's a daily-life intervention. You take a tiny amount, you go to work, you make dinner, you talk to your kid about their math homework. The changes — if they come — accumulate slowly and feel like small adjustments in temperament. Some people find this more useful than the big ceremonial work. Others find it doesn't touch the root of what they're carrying, and they end up booking a retreat anyway. Many do both: microdose between ceremonies as a way of staying in dialogue with what came up. The intersection of psychedelics and addiction recovery is where the most genuinely exciting research is happening. Johns Hopkins, NYU, and several European universities have run trials using psilocybin for tobacco cessation and alcohol use disorder, with results that — while early — outperform most existing treatments. Ibogaine, a far more intense plant medicine, has a long underground track record with opioid dependence; people fly to Mexico or Costa Rica for ibogaine treatment when nothing else has worked. Microdosing is a softer tool, and I want to be careful here. If you're in active addiction, microdosing on your own is not a treatment plan. It's a supplement at best and a distraction at worst. The people who've used small doses successfully in recovery almost always have something else in place — a therapist, a support group, a clear protocol, sometimes a residential program that included a higher-dose psychedelic experience as the actual turning point. The pattern I see again and again: a single significant ceremony (ayahuasca, psilocybin, ibogaine, sometimes San Pedro) creates a window of clarity. Microdosing helps keep that window open while the person rebuilds the rest of their life. The ceremony alone fades. The microdose alone may not be enough to break through. Together, with real human support, the combination has changed lives. This part doesn't get said enough. For many people researching microdosing, the underlying question isn't really about microdosing at all. It's: am I willing to do something bigger? A retreat — psilocybin in Jamaica, ayahuasca in Peru or Costa Rica, ibogaine in Mexico — is a substantial commitment of money, time, and emotional bandwidth. It also tends to produce results that microdosing alone won't. If you're at that crossroads, a few honest things to weigh: what you're hoping to address, whether you have integration support available afterward (this matters more than the ceremony itself), the reputation and lineage of the facilitators, and whether the center is upfront about screening for medical and psychiatric contraindications. Any retreat that doesn't ask thorough medical questions before accepting you should be a hard pass. For readers who want to take this further, a curated selection of psychedelic and plant-medicine retreats can be browsed on our marketplace here. Whether you end up booking one or not, reading through what's actually offered — the durations, the protocols, the aftercare — is one of the better ways to understand what serious psychedelic healing looks like in practice. The decision to work with psychedelics, in any dose, is personal and worth taking slowly. Curiosity is healthy. Hype is not. Trust the version of yourself that's still asking questions.
Ayahuasca and Grief: What Prince Harry's Story Reveals About Plant Medicine Healing
A 12-year-old boy loses his mother in one of the most public tragedies of the late twentieth century. He doesn't cry. Not really. Not for years. He grows into a man who carries that silence like a second skeleton — and then, somewhere in his late thirties, he drinks a bitter Amazonian brew under the care of facilitators and something finally gives way. That's the story Prince Harry told a journalist not long ago, and whatever you think of the man or the monarchy, the disclosure mattered. Ayahuasca, once a fringe curiosity, keeps surfacing in the lives of people who've tried everything else. Veterans. Recovering addicts. Therapists. And now a duke. The interesting question isn't whether his experience was real to him — clearly it was — but what it tells the rest of us about plant medicine, grief, and the long shadow of trauma that ordinary talk therapy sometimes can't reach. The short version: he'd convinced himself, somewhere deep down, that crying was the only proof of love he could offer his mother. If he wasn't weeping, he wasn't grieving properly. If he wasn't grieving properly, he was a bad son. That story had been running in the background of his life for decades. Under ayahuasca, with what he called “the proper people” around him, the script collapsed. He described a sudden clarity — that his mother wanted him happy, not theatrically broken. The weight he'd been carrying wasn't an unmet duty to cry. It was the refusal to accept she was actually gone, paired with the belief that joy would somehow betray her memory. That's a remarkably specific insight to come out of a single ceremony. And it's also exactly the kind of insight ayahuasca facilitators hear repeated, in different shapes, from participant after participant. The medicine doesn't give people new information so much as it dismantles the protective stories they've built around old information. Talk therapy is brilliant at many things. Sitting with a grief that's been frozen since childhood is sometimes not one of them. The reason is mechanical, not mystical. When a child experiences something the nervous system can't process — a parent's sudden death, a car crash on a Paris road, a funeral watched by a billion strangers — the body files the experience somewhere language can't easily reach. You can talk about it for years and still feel nothing. Ayahuasca and other psychedelic medicines appear to loosen that filing system. The default-mode network — the part of the brain that runs your familiar self-story on a loop — quiets down. Memories surface with their emotional charge intact, sometimes for the first time. People weep over losses they thought they'd processed. They feel rage they didn't know they were carrying. They forgive people they didn't know they hadn't forgiven. None of this is magic, and it isn't a shortcut either. The medicine opens a door. Walking through it is still the participant's work. Here's where it gets interesting. The clinical research, while still early, keeps pointing in a consistent direction. Studies on ayahuasca-assisted treatment for depression, PTSD, and substance dependence have shown meaningful reductions in symptoms — often after just a handful of ceremonies, and often holding up months later. Observational work with long-term ceremony participants tends to find lower rates of problem drinking and drug use than in matched populations. This isn't proof of a cure. It's proof that something interesting is happening that deserves more research. The combination of DMT and the MAO inhibitors in the ayahuasca vine appears to do something that synthetic psychedelics alone don't quite replicate — a longer, more emotionally textured experience that seems to lend itself to autobiographical work. For people stuck in patterns — the same depressive loop, the same drink at 6 p.m., the same relationship dynamic with three different partners — master plants like ayahuasca, iboga, and psilocybin can break the pattern's grip long enough for a person to see it from the outside. Whether they choose to live differently afterward is, again, on them. Harry mentioned in passing that his ayahuasca experience created distance between him and his older brother. That detail deserves more attention than it usually gets in these stories. Plant medicine changes people. Not always dramatically, not always permanently, but often enough that family members notice. The person who comes home from a retreat sometimes sees old relationships differently. They have less patience for certain dynamics. They want to talk about things the family doesn't want to discuss. They've been somewhere the people they love haven't, and there's no easy way to share the territory. This is one of the genuinely difficult costs of doing this work, and reputable retreats will talk about it during preparation. If you're considering a ceremony, expect that: None of this is a reason not to go. It's a reason to choose carefully and prepare honestly. The phrase Harry used — taking ayahuasca with “the proper people” — is doing a lot of quiet work in that sentence. The difference between a well-run ceremony and a poorly run one is the difference between cathartic and catastrophic. If you're looking at retreats, the questions worth asking are unglamorous and specific: Cost varies wildly, from a few hundred dollars for a single ceremony in a city to several thousand for a week in Peru or Costa Rica. Higher price doesn't guarantee quality, but suspiciously cheap usually means corners cut. You don't need a public tragedy to qualify. Grief doesn't grade itself. A parent who died when you were a child, a divorce you never quite recovered from, a friend lost to suicide, a version of yourself that disappeared somewhere along the way — these are all reasons people end up sitting in ceremony. Two honest cautions, though. First, ayahuasca is not a single dose of healing. People who walk in expecting one night to fix twenty years of pain usually walk out disappointed, or worse, destabilised. The medicine tends to show you what needs work, not do the work for you. Second, the post-ceremony period matters more than the ceremony itself. Plan for it. Take time off afterward. Have a therapist lined up. Don't book a retreat the week before a major work deadline or your sister's wedding. Treat integration as part of the cost, not an afterthought. For readers who want to take this further, a range of vetted ayahuasca retreats can be browsed on our marketplace here. Whether or not booking one ends up being the right call for you, the decision deserves the time you're already giving it.
What Celebrity Ayahuasca Stories Actually Tell Us About Real Ceremonies
Every couple of months, a celebrity comes back from Costa Rica or Peru and tells a late-night host they drank ayahuasca and went to hell. The clip goes viral. The comments split between “sounds horrifying” and “where do I sign up.” And somewhere in the middle, a real person — maybe you — is sitting with a browser tab open, wondering whether any of this applies to their actual life. It's a fair question. Ayahuasca is having a long, loud cultural moment, and the loudest voices in it are not always the most useful ones. So let's take a famous account — the one where Megan Fox described her ceremony in Costa Rica as both “hell” and a “good bonding experience” — and use it as a way into the stuff that actually matters when you're considering a psychedelic retreat for yourself. Fox said she went in thinking the retreat would be “five-star” — some kind of upscale jungle experience with nice sheets and a wellness menu. What she got was the middle of the jungle, no food after 1 p.m., and a maloca full of strangers preparing to drink a bitter brown brew. This is one of the most common mismatches between expectation and reality, and it trips up a lot of first-timers. The retreats getting the most legitimate work done are usually not the ones with infinity pools and turndown service. Traditional plant medicine work tends to be physically simple on purpose. You sleep in a basic cabin. You eat plain food — no salt, no sugar, no oil, no meat, depending on the lineage. You sweat. You sit in silence. The point isn't deprivation as virtue; it's that ayahuasca works on a body and mind that haven't been buffered by comfort all week. If you find yourself comparing retreats and one of them mentions spa treatments and gourmet menus alongside the ceremony schedule, that's worth a second look. Not automatically a red flag — some hybrid places do solid work — but ask the obvious question: what's the dieta, and who's leading the ceremonies? Ayahuasca is a brew, not a single drug. The two essential ingredients are the Banisteriopsis caapi vine and a DMT-containing leaf, usually chacruna (Psychotria viridis). The vine contains MAO inhibitors that allow the DMT in the leaf to become orally active — without that combination, you'd just digest the DMT and feel nothing. This is genuinely one of the more remarkable pieces of ethnobotanical knowledge on the planet, given that the people who figured it out did so without a chemistry lab. The reason this matters for you, the prospective drinker, is that the MAOI component is what creates the dieta requirements you'll read about — no tyramine-rich foods, no SSRIs, no certain medications, no recreational drugs in the lead-up. These aren't optional preferences. Mixing ayahuasca with the wrong substance can be dangerous in ways that have nothing to do with the psychedelic experience. Any retreat worth its salt will send you a detailed medical and dietary screening before they take your deposit. If they don't, walk. Fox described the ceremony beginning with everyone drinking lemongrass tea to induce vomiting together — what she called a “good bonding experience.” For anyone reading this and recoiling: yes, that's a real thing, and yes, it's part of the territory. The traditional word for it is la purga. The purge. Ayahuasca itself frequently induces vomiting, and most lineages frame this not as an unpleasant side effect but as a central feature — the body releasing what the mind has been holding. Some ceremonies open with a separate emetic to clear the system first; others let the brew do that work on its own. Either way, by night two or three, you've stopped being precious about it. Things that are normal during an ayahuasca ceremony and that no one warns you about clearly enough: None of this is failure. All of it is the medicine doing exactly what people have used it to do for centuries. If you go in expecting a clean, dignified, Instagram-friendly experience, you're going to fight the process. Surrendering to the mess is, in a real sense, the work. The most quoted part of Fox's account is the bit about feeling like she was in hell for eternity, with no beginning, middle, or end — and then her ego dying. That phrasing tends to either fascinate people or freak them out. Here's what it actually points to. Ego death, in the psychedelic sense, isn't a metaphor for feeling humble. It's a specific experience where the usual sense of being a continuous self — the narrator in your head — temporarily dissolves. People describe it as terrifying, liberating, or both. The “eternity” language comes from the fact that during these experiences, time doesn't work the way it normally does. Five minutes can feel like a lifetime. There's no clock, no anchor, no exit door you can locate. This is also where the therapeutic potential lives, and why ayahuasca and other plant medicines are being seriously studied for addiction, depression, and trauma. When the usual self goes offline, the rigid stories you tell about who you are and what's wrong with you — the “psychological prison,” to borrow the phrase — can loosen enough that something else becomes possible. People who have been stuck in patterns for decades sometimes report a single ceremony shifting something that years of talk therapy couldn't reach. Sometimes. Not always. Anyone who promises you healing as an outcome is selling, not telling. This is the question worth sitting with. A celebrity describing a difficult-but-meaningful ceremony on a talk show is entertainment. Your decision to spend two thousand dollars and a week of your life on a plant medicine retreat is not. Honest reasons to consider an ayahuasca retreat: Reasons to wait, or to choose something gentler: The plant medicine space has grown faster than its quality controls. There are extraordinary, lineage-rooted centers run by people who have been doing this for decades. There are also opportunists who watched the trend and opened a center last year. Telling them apart requires asking better questions than most websites will answer on their landing page. Some things to ask before you book: If something here speaks to you, the available ayahuasca and plant-medicine retreats can be browsed and booked on our marketplace here. Read carefully, ask the awkward questions, and trust your gut on the answers — the right ceremony at the right time can be quietly life-changing, and the wrong one is mostly just expensive.
Dreaming of a Psychedelic Retreat?
We have the best deals and offers from thousands of organizers all over the world! Get them into your mailbox every week!
We value your privacy. Your email address will never be shared or published.
